Kite treated patients with its an anti-CD19 chimeric antigen receptor (CAR) T cell therapy called KTE-C19. Eight of 13 patients with Advanced B cell malignancies showed complete remissions, while four showed partial remissions. The total result was a 92% objective response rate.
Furthermore, four of seven patients with chemotherapy-refractory diffuse large B-cell Lymphoma showed complete remissions. Three of these cases are ongoing, while one is ongoing after 22 months.
The company published the data from the trial in the Aug. 25 issue of the Journal of Clinical Oncology. James N. Kochenderfer, M.D., one of the authors of the study, presented earlier data from the trial for the National Cancer Institute at the 55th American Society of Hematology Annual Meeting in Dec. 2013.
The stock was up 15.56% to $25.77 at 11:20 a.m. More than 3.8 million shares changed hands, compared to the average volume of 395,300.KITE data by YCharts
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.